WHO ICTRP trial
Phase II study of nedaplatin plus irinotecan for stage III/IV squamous cell lung…
JPRN-UMIN000003330 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-UMIN000003330 |
|---|---|
| Public title | Phase II study of nedaplatin plus irinotecan for stage III/IV squamous cell lung cancer (TORG0910) |
| Scientific title | Phase II study of nedaplatin plus irinotecan for stage III/IV squamous cell lung cancer (TORG0910) - Phase II study of nedaplatin plus irinotecan for squamous cell lung cancer |
| Primary sponsor | Thoracic Oncology Research Group (TORG) |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase II |
| Countries | Japan |
| Conditions | Unresectable stage III/IV and relapsed after resection squamous cell lung cancer |
| Interventions | nedaplatin 100mg/m2 (day1) and irinotecan 60mg/m2 (day1,8), every 4-5 weeks, total 4-6 courses |
| Registration date | Mar 15, 2010 |
| Target size | 50 |
| Registry page | center6.umin.ac.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: